Lantheus (NASDAQ:LNTH) Hits New 12-Month High – Still a Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $107.99 and last traded at $106.8160, with a volume of 147583 shares changing hands. The stock had previously closed at $106.20.

Wall Street Analyst Weigh In

A number of analysts have commented on LNTH shares. Citizens Jmp boosted their price target on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Mizuho boosted their price target on shares of Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 27th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Performance

The firm’s 50-day moving average price is $94.84 and its two-hundred day moving average price is $79.34. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $6.83 billion, a PE ratio of 25.27 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the prior year, the firm earned $1.53 EPS. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts predict that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Western Wealth Management LLC acquired a new stake in Lantheus during the 1st quarter worth about $25,000. Smartleaf Asset Management LLC grew its stake in Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares during the period. Osterweis Capital Management Inc. acquired a new position in shares of Lantheus in the 2nd quarter valued at about $36,000. Finally, Bessemer Group Inc. lifted its position in shares of Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 354 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.